Show simple item record

AuthorShona, Pedersen
AuthorHansen, Joachim Bavnhøj
AuthorMaltesen, Raluca Georgiana
AuthorSzejniuk, Weronika Maria
AuthorAndreassen, Trygve
AuthorFalkmer, Ursula
AuthorKristensen, Søren Risom
Available date2021-10-21T09:04:26Z
Publication Date2021-12-31
Publication NameMetabolism Open
Identifierhttp://dx.doi.org/10.1016/j.metop.2021.100127
CitationPedersen, S., Hansen, J. B., Maltesen, R. G., Szejniuk, W. M., Andreassen, T., Falkmer, U., & Kristensen, S. R. (2021). Identifying metabolic alterations in newly diagnosed small cell lung cancer patients. Metabolism open, 100127.
ISSN25899368
URIhttps://www.sciencedirect.com/science/article/pii/S2589936821000517
URIhttp://hdl.handle.net/10576/24630
AbstractBackgroundSmall cell lung cancer (SCLC) is a malignant disease with poor prognosis. At the time of diagnosis most patients are already in a metastatic stage. Current diagnosis is based on imaging, histopathology, and immunohistochemistry, but no blood-based biomarkers have yet proven to be clinically successful for diagnosis and screening. The precise mechanisms of SCLC are not fully understood, however, several genetic mutations, protein and metabolic aberrations have been described. We aim at identifying metabolite alterations related to SCLC and to expand our knowledge relating to this aggressive cancer. MethodsA total of 30 serum samples of patients with SCLC, collected at the time of diagnosis, and 25 samples of healthy controls were included in this study. The samples were analyzed with nuclear magnetic resonance spectroscopy. Multivariate, univariate and pathways analyses were performed. ResultsSeveral metabolites were identified to be altered in the pre-treatment serum samples of small-cell lung cancer patients compared to healthy individuals. Metabolites involved in tricarboxylic acid cycle (succinate: fold change (FC) = 2.4, p = 0.068), lipid metabolism (LDL triglyceride: FC = 1.3, p = 0.001; LDL-1 triglyceride: FC = 1.3, p = 0.012; LDL-2 triglyceride: FC = 1.4, p = 0.009; LDL-6 triglyceride: FC = 1.5, p < 0.001; LDL-4 cholesterol: FC = 0.5, p = 0.007; HDL-3 free cholesterol: FC = 0.7, p = 0.002; HDL-4 cholesterol FC = 0.8, p < 0.001; HDL-4 apolipoprotein-A1: FC = 0.8, p = 0.005; HDL-4 apolipoprotein-A2: FC ≥ 0.7, p ≤ 0.001), amino acids (glutamic acid: FC = 1.7, p < 0.001; glutamine: FC = 0.9, p = 0.007, leucine: FC = 0.8, p < 0.001; isoleucine: FC = 0.8, p = 0.016; valine: FC = 0.9, p = 0.032; lysine: FC = 0.8, p = 0.004; methionine: FC = 0.8, p < 0.001; tyrosine: FC = 0.7, p = 0.002; creatine: FC = 0.9, p = 0.030), and ketone body metabolism (3-hydroxybutyric acid FC = 2.5, p < 0.001; acetone FC = 1.6, p < 0.001), among other, were found deranged in SCLC. ConclusionsThis study provides novel insight into the metabolic disturbances in pre-treatment SCLC patients, expanding our molecular understanding of this malignant disease.
Languageen
PublisherElsevier
SubjectSmall-cell lung cancer
Metabolomics
Serum metabolites
Pathways
Diagnostic signatures
TitleIdentifying metabolic alterations in newly diagnosed small cell lung cancer patients
TypeArticle
Volume Number12
Open Access user License http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record